Overview

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This is an efficacy and safety study evaluating a new treatment for subjects with mild to moderate Alzheimer's disease.
Phase:
Phase 2
Details
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Treatments:
Donepezil